A PP2A-Integrator complex fine-tunes transcription by opposing CDK9

ABSTRACT: Gene expression by RNA Polymerase II (RNAPII) is tightly controlled by Cyclindependent kinases (CDKs) at discrete checkpoints during the transcription cycle. The RNAPII pausing checkpoint, engaged after transcription initiation, is controlled by CDK9 to regulate transcription in metazoans. We discovered that CDK9-mediated RNAPII pause-release is functionally opposed by a protein phosphatase 2A (PP2A) complex. PP2A dynamically competes for key CDK9 substrates, DSIF and RNAPIICTD, and is recruited to transcription pausing sites by the Integrator complex subunit INTS6. INTS6 depletion confers resistance to CDK9 inhibition in a variety of normal and tumor cell lines. Loss of INTS6 abolishes the Integrator-PP2A association leading to unrestrained CDK9 activity, which amplifies transcriptional responses. Pharmacological PP2A activation synergizes with CDK9 inhibition to kill MLLrearranged leukemias and solid tumors and provide therapeutic benefit in vivo. These data demonstrate that finely-tuned gene expression relies on the balance of kinase and phosphatase activity at the pausing checkpoint.

INSTRUMENT(S): Q Exactive

ORGANISM(S): Homo Sapiens (human) Drosophila Melanogaster (fruit Fly) Mus Musculus (mouse)

TISSUE(S): Blood Cell

DISEASE(S): Acute Leukemia

SUBMITTER: Jarrod Sandow  

LAB HEAD: Ricky Johnstone

PROVIDER: PXD022962 | Pride | 2022-08-12

REPOSITORIES: Pride